NYSE$PFE
Pfizer · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Pfizer reported strong financial results for Q1 2021, driven by BNT162b2 vaccine and overall business performance, and raised its full-year 2021 guidance.
Pfizer's Q1 2021 revenues reached $14.6 billion, reflecting a 42% operational growth. Excluding BNT162b2 vaccine revenues, the company still achieved an 8% operational growth. The company raised its full-year 2021 revenue guidance to $70.5 to $72.5 billion and adjusted diluted EPS to $3.55 to $3.65.
- Q1 2021 revenues totaled $14.6 billion, a 45% increase compared to the prior-year quarter, with operational growth of 42%.
- Reported diluted EPS was $0.86, and adjusted diluted EPS was $0.93.
- The company raised its full-year 2021 revenue guidance to a range of $70.5 to $72.5 billion and adjusted diluted EPS to a range of $3.55 to $3.65.
- BNT162b2 contributed $3.5 billion in global revenues.
Headline financials
Revenue & EPS history
Pfizer · Revenue · Quarterly
$14.6B
Revenue by segment
Pfizer · $12.9B total across 1 segment · Q3 2023
- Biopharma$12.9B-42.1%100.0%
Forward guidance
Pfizer raises its guidance ranges for revenues, Adjusted cost of sales as a percentage of revenues, Adjusted R&D expenses and Adjusted diluted EPS to reflect the updated expectations for contributions to 2021 performance from BNT162b2 and the continued strong performance of the business excluding BNT162b2, partially offset by anticipated additional R&D investments into vaccines to protect against COVID-19, as well as early research investments into other mRNA-based development programs and COVID-19 antivirals.
Tailwinds
- Revenues: $70.5 to $72.5 billion (previously $59.4 to $61.4 billion)
- Adjusted Cost of Sales as a Percentage of Revenues: 38.0% to 39.0% (previously 32.0% to 33.0%)
- Adjusted SI&A Expenses: $11.0 to $12.0 billion
- Adjusted R&D Expenses: $9.8 to $10.3 billion (previously $9.2 to $9.7 billion)
- Adjusted Diluted EPS: $3.55 to $3.65 (previously $3.10 to $3.20)
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2021
-0.3%
Avg return
Earnings day
-0.3%
Avg return
5 days after
+0.1%
Avg return
30 days after
50%
36 / 72 earnings
Positive
+8.1%
Q1 2024
Best reaction
-10.0%
Q2 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.2% | -2.5% | -2.3% | |
| Q4 2025 | -3.3% | +2.1% | -0.2% | |
| Q3 2025 | -1.5% | -0.9% | +4.2% | |
| Q1 2025 | +3.2% | +5.0% | +1.7% | |
| Q4 2024 | -1.3% | -1.8% | +0.2% | |
| Q3 2024 | -1.2% | -2.7% | -10.5% | |
| Q2 2024 | -0.6% | -0.9% | -6.5% | |
| Q1 2024 | +8.1% | +9.9% | +11.9% | |
| Q4 2023 | -1.5% | -2.0% | -3.3% | |
| Q3 2023 | -0.1% | +2.3% | -0.3% | |
| Q2 2023 | -2.0% | -2.9% | -1.9% | |
| Q1 2023 | -1.9% | -1.8% | -3.0% | |
| Q4 2022 | +1.0% | +1.2% | -6.7% | |
| Q3 2022 | +1.1% | +1.4% | +9.7% | |
| Q2 2022 | -2.8% | -4.4% | -9.9% | |
| Q1 2022 | +2.7% | +1.4% | +9.0% | |
| Q4 2021 | -3.3% | -4.6% | -7.5% | |
| Q3 2021 | +2.7% | +11.4% | +21.5% | |
| Q2 2021 | +1.6% | +4.4% | +10.7% | |
| Q1 2021 | +0.4% | -0.6% | -2.2% | |
| Q4 2020 | -2.7% | -2.5% | -4.5% | |
| Q3 2020 | -6.5% | -6.4% | +1.5% | |
| Q2 2020 | +4.6% | +2.5% | +0.9% | |
| Q1 2020 | -0.5% | -1.8% | -0.4% | |
| Q4 2019 | -6.4% | -7.3% | -15.1% | |
| Q3 2019 | +3.2% | +3.0% | +3.6% | |
| Q2 2019 | -10.0% | -11.8% | -18.6% | |
| Q1 2019 | +3.0% | +4.5% | +5.8% | |
| Q4 2018 | +5.2% | +8.5% | +9.7% | |
| Q3 2018 | -0.4% | -0.7% | +5.3% | |
| Q2 2018 | +4.3% | +5.1% | +7.5% | |
| Q1 2018 | -4.7% | -4.8% | -1.9% | |
| Q4 2017 | -5.1% | -6.2% | -8.7% | |
| Q3 2017 | +0.3% | +1.1% | +3.2% | |
| Q2 2017 | -0.7% | +1.4% | +2.3% | |
| Q1 2017 | -0.9% | -0.9% | -3.2% | |
| Q4 2016 | +1.1% | +2.5% | +10.2% | |
| Q3 2016 | -3.4% | -5.4% | -0.8% | |
| Q2 2016 | -5.4% | -5.0% | -7.0% | |
| Q1 2016 | +1.8% | — | — | |
| Q4 2015 | -1.6% | — | — | |
| Q3 2015 | +3.8% | — | — | |
| Q2 2015 | +4.1% | — | — | |
| Q1 2015 | -0.9% | — | — | |
| Q4 2014 | -2.6% | — | — | |
| Q3 2014 | +1.6% | — | — | |
| Q2 2014 | -2.8% | — | — | |
| Q1 2014 | -4.3% | — | — | |
| Q4 2013 | +1.5% | — | — | |
| Q3 2013 | +0.6% | — | — | |
| Q2 2013 | -1.0% | — | — | |
| Q1 2013 | -5.0% | — | — | |
| Q4 2012 | +2.5% | — | — | |
| Q3 2012 | -1.3% | — | — | |
| Q2 2012 | +0.9% | — | — | |
| Q1 2012 | +0.9% | — | — | |
| Q4 2011 | -0.6% | — | — | |
| Q3 2011 | +3.4% | — | — | |
| Q2 2011 | +4.8% | — | — | |
| Q1 2011 | +0.8% | — | — | |
| Q4 2010 | +1.5% | — | — | |
| Q3 2010 | -1.4% | — | — | |
| Q2 2010 | +0.5% | — | — | |
| Q1 2009 | -4.1% | — | — | |
| Q1 2010 | -1.1% | — | — | |
| Q4 2007 | +0.4% | — | — | |
| Q4 2009 | +0.4% | — | — | |
| Q3 2008 | +0.2% | — | — | |
| Q3 2009 | +0.2% | — | — | |
| Q4 2008 | +0.6% | — | — | |
| Q2 2008 | +0.6% | — | — | |
| Q2 2009 | +0.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro